Streetbeat News

Price Targets

SMTC

Needham analyst Quinn Bolton has maintained a Buy rating on Semtech (NASDAQ:SMTC) but reduced the price target from $35 to $26.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:52 am

TOL

Barclays analyst Matthew Bouley has maintained an Underweight rating on Toll Brothers (NYSE:TOL) but increased the price target from $74 to $95.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:50 am

BNED

Needham analyst Ryan MacDonald has reiterated a Buy rating on Barnes & Noble Education (NYSE:BNED) and maintained a $4 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:49 am

TIMB

Barclays analyst Mathieu Robilliard has maintained an Equal-Weight rating on TIM (NYSE:TIMB) and increased the price target from $18 to $19.4.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:48 am

ACRX

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on AcelRx Pharmaceuticals (NASDAQ:ACRX) and maintained a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:45 am

LUMO

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Lumos Pharma (NASDAQ:LUMO) and maintained a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:43 am

CDTX

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $6 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:39 am

BNOX

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Bionomics (NASDAQ:BNOX) and maintained an $8 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:38 am

RYTM

Needham analyst Joseph Stringer has reaffirmed a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and increased the price target from $32 to $45.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:36 am

IPSC

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Century Therapeutics (NASDAQ:IPSC) and maintained a $13 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 11:32 am